Muse Screener — India

Verdict: A superb duopoly business, but fairly priced at ~33x FY27E earnings — hold at this price and buy on tariff or Africa-led weakness.

Moat: One of only two viable pan-India telecom operators in a consolidated duopoly with Jio, with spectrum, tower and fibre scale no new entrant can replicate.

Bull: Q2 FY27 (announced 5 Nov 2026) revenue rose 16.7% YoY to ₹60,878 crore and net profit 23.8% to ₹10,710 crore, with ARPU up to ₹271 and record postpaid adds of 1.2 million.

Bear: At 42.1x TTM earnings and ~₹1.95 lakh crore of borrowings, the stock already prices in the next tariff hike, and on 6 Nov it reclaimed India's No.2 market-cap spot at ₹13.15 lakh crore — little margin for a tariff delay.

Verdict: A high-quality franchise at a historically cheap multiple, but with growth still subdued — a buy for patient holders, not a momentum trade.

Moat: India's largest private-sector bank by assets, with a ~₹33 lakh crore deposit base and the widest retail distribution network among private banks.

Bull: Q2 FY27 net profit rose 5.8% YoY to ₹21,537 crore with gross NPA down to 1.11%, and the stock trades at 15.2x TTM earnings — its 7th percentile versus its own 5-year P/E range — after a ~20% one-year fall.

Bear: Loan and earnings growth have slowed to single digits (TTM sales +4%, Q2 profit +5.8%), NIM was at a trough of 3.16% in Q2 FY27, and a new MD & CEO (Anup Bagchi, from 27 Oct 2026) takes over mid-turnaround.

Verdict: The best-run large private bank in India, but at a record high after a vertical week — hold, and add on dips rather than chase.

Moat: India's second-largest private bank, with a granular ₹18.3 lakh crore deposit franchise, sector-leading return ratios and a fortress capital position.

Bull: Q2 FY27 net profit jumped 21.4% YoY to ₹17,389 crore on revenue up 16.2%, with ROE ~16-17% and the stock at 19.1x TTM earnings — near its 5-year median P/E despite the growth.

Bear: The stock closed at a 52-week/all-time high of ₹1,571.20 on 6 Nov after rising 12.4% in five sessions, so the strong Q2 print is already in the price and any NIM or credit-cost wobble invites a sharp pullback.

Verdict: The cheapest mega-cap bank in India, with a strong Q2 print and a wide discount to its own high — a buy at ₹1,019.

Moat: India's largest bank by assets, deposits (₹60.4 lakh crore) and branches, with implicit sovereign backing and a ~55.5% government stake.

Bull: Q2 FY27 net profit rose 19.9% YoY to ₹26,218 crore, management guides 14-15% loan growth and domestic NIM above 3% in FY27, and the stock trades at just 11.0x earnings and 1.4x book — 17% below its ₹1,234.70 52-week high.

Bear: Earnings growth is set to slow sharply (Motilal Oswal FY27E EPS growth only 4.7%), NIMs face deposit-cost pressure, and PSU-bank valuations have historically de-rated whenever government ownership or asset-quality fears resurface.

Verdict: Unmatched order visibility, but margin pressure and a full 30x multiple leave little upside at ₹4,118 — hold.

Moat: India's dominant EPC contractor with unmatched execution scale, a ₹8.54 lakh crore order book (2.6x FY26 revenue) and valuable listed subsidiaries (LTI Mindtree, L&T Finance, LTTS).

Bull: Q2 FY27 was a record quarter — order inflow up 28% YoY to ₹1,47,665 crore, order book ₹8,53,514 crore, revenue +15.8% to ₹78,750 crore and PAT +33% to ₹5,202 crore (attributable).

Bear: EBITDA grew only 1% YoY to ₹6,845 crore despite 16% revenue growth, with project margins squeezed by Middle-East supply-chain disruption, and the stock trades at 30x TTM earnings.

Verdict: A wide-moat monopoly at a full 43x trailing earnings with shrinking TTM revenue — quality to own, but no mispricing at Rs 1,908, so hold.

Moat: India's dominant stock exchange and the world's largest derivatives exchange by volume, with a near-monopoly network effect and a regulatory licence no rival can replicate.

Bull: Morgan Stanley initiated coverage with Overweight and a Rs 2,315 target (about 30% above the Nov 2 price) and JPMorgan holds Overweight at Rs 2,130, after Q2 FY27 PAT beat estimates at Rs 25.6 billion.

Bear: TTM revenue is down about 5% and TTM profit down about 12% as derivatives volumes cool, yet the stock still trades at roughly 43x trailing earnings after listing at only a 0.8% premium to its IPO price.

Verdict: A monopoly order book with multi-year visibility, but priced for flawless execution at 33x FY27E earnings — hold, and buy the engine-delay dips.

Moat: India's sole domestic military-aircraft manufacturer — a government-owned Maharatna with a ₹2,54,538 crore order book (7-8 years of revenue) and no domestic competitor for Tejas, helicopters and aero-engines.

Bull: Q1 FY27 revenue rose 14.4% YoY to ₹5,515 crore with net profit +14.9%, management targets ~20 Tejas deliveries in FY27, and ICICI Securities/Motilal Oswal both rate it BUY with targets of ₹5,300-5,800.

Bear: At 35.7x TTM earnings and 8.1x book, the stock is expensive for a company whose working-capital days ballooned from 153 to 301, and Tejas Mk1A deliveries remain hostage to imported-engine supply.

Verdict: Cheap at ~10.5x trailing earnings with a ~2.8% yield, but low single-digit growth makes it a hold, not a bargain to chase.

Moat: India's largest power generator with regulated cost-plus returns and huge scale, but tariffs are regulated and coal exposure caps pricing power.

Bull: Q2 FY27 consolidated revenue rose 21% YoY to Rs 54,270 crore and net profit jumped 41% to Rs 7,351 crore, with a Rs 3 interim dividend and ~9.6 GW of capacity additions guided for FY27.

Bear: FY26 revenue was flat (-0.4% YoY), the stock is ~22% below its Rs 414.40 52-week high, and MarketsMojo downgraded it to Sell on 2 November 2026 citing management efficiency and debt.

Verdict: Execution is strong and the pipeline is huge, but 41x FY27E earnings leaves no room for a QRSAM slip — hold.

Moat: India's dominant defence-electronics supplier (Navratna, 51.1% government-owned), with ~90% of its ₹68,717 crore order book on nomination basis and entrenched positions in radars, EW and missile electronics.

Bull: Q2 FY27 revenue jumped 26.5% YoY to ₹7,328 crore with PAT +19.7% to ₹1,540 crore, H1 revenue is already +26% versus 15%+ full-year guidance, and HSBC/ICICI Direct hold BUY ratings with targets up to ₹530.

Bear: At 45.2x TTM earnings and 11.0x book, BEL is the most expensive name in this set, and the order book actually shrank 7.7% YoY to ₹68,717 crore — the ₹50,000+ crore QRSAM inflow it depends on is still awaiting approval.

Verdict: A wide-moat compounder at a fair ~29x FY27E earnings, fairly priced after the run — hold, add on dips.

Moat: India's largest private port operator handling ~27% of national cargo, with integrated logistics, SEZ and marine assets that are hard to replicate.

Bull: Q2 FY27 revenue rose 24% YoY to Rs 11,340 crore and management raised FY27 revenue and EBITDA guidance by Rs 1,000 crore each, with ICICI Direct retaining BUY and a Rs 2,210 target.

Bear: The stock closed at Rs 1,936.60, near its 52-week high, after a heavy Rs 90,000 crore FY26-31 capex plan and the Evos B.V. acquisition add leverage and execution risk.

Verdict: A wide-moat regulated annuity at a fair ~14x forward earnings with a ~3.4% yield — a hold for income, not a growth buy.

Moat: Near-monopoly owner-operator of India's inter-state transmission grid (187,576 ckm, 293 substations) earning regulated annuity returns with 99.81% system availability.

Bull: Q2 FY27 consolidated PAT rose 8.4% YoY to Rs 3,866 crore, FY27 capex guidance is Rs 37,000-40,000 crore, and the works-in-hand pipeline is ~Rs 2.2 lakh crore with a Rs 3 interim dividend.

Bear: Sales grew only 3% TTM and ~1% over 3 years, the stock is in a Stage 4 downtrend ~20% below its Rs 324.95 52-week high, and H1 capitalisation (Rs 9,300 Cr) lagged capex (Rs 16,864 Cr).

Verdict: A wide-moat exchange monopoly growing fast, but ~44x forward earnings with regulatory overhang makes it a hold at this price.

Moat: Asia's oldest exchange in a two-exchange duopoly with NSE, with network effects across equities, derivatives and the StAR MF platform and a debt-free, 65% operating-margin model.

Bull: Q2 FY27 revenue rose 34% YoY to Rs 1,433 crore and net profit 45% to Rs 808 crore, F&O notional volumes surged 85% in October, and Motilal Oswal upgraded to BUY with a Rs 4,000 target ahead of the 7 Dec partial CAS reversal.

Bear: Earnings are hostage to SEBI rule changes on derivatives (higher STT, collateral rules), and at ~44x FY27E earnings with FY28E PAT growth forecast to slow sharply, the margin of safety is thin.

Verdict: The turnaround is real and the backlog is enormous, but at ~40x forward earnings on thin margins it is a hold, not a chase.

Moat: India's dominant power-equipment PSU with unmatched BTG manufacturing scale and a Rs 2.58 lakh crore order book, but returns have historically been thin and execution is PSU-paced.

Bull: Q2 FY27 revenue rose 23.8% YoY to Rs 9,300 crore with PAT of Rs 810 crore, and on 4 Nov it won four Adani Power BTG orders worth Rs 5,000-7,000 crore each, lifting the pro-forma order book to ~Rs 2.86 lakh crore.

Bear: Even after the turnaround, TTM net margin is only 7.6% and ROE ~6%, so at ~40x FY27E earnings the stock is priced for flawless execution of a 7.6x book-to-bill backlog.

Verdict: A superb 55%-margin AMC growing mid-teens, but at ~34x forward earnings with fee-yield compression ahead it is fairly priced — hold at Rs 2,936.

Moat: India's second-largest mutual fund manager with 13.3% share and leadership in active equity/hybrid schemes, but fees are capped by SEBI TER limits and AUM can walk to rivals.

Bull: Q2 FY27 mutual-fund average AUM rose 4% sequentially to Rs 11.6 lakh crore, revenue yield firmed to 57.5 bps, and Emkay retained BUY with a Sep 2027 target of Rs 3,800, about 28% above the Oct 13 close.

Bear: Q2 FY27 net profit fell 8% sequentially to Rs 889 crore as treasury mark-to-market losses collapsed other income to Rs 16.9 crore from Rs 180.8 crore, and the stock sits 17% below its 52-week high of Rs 3,611 in a Stage 4 downtrend.

Verdict: The best retail-broking franchise in India growing ~50%, but at ~39x forward earnings the market already knows it — hold at Rs 215.

Moat: India's largest retail broker with roughly 30% market share and a debt-free, high-ROE platform, but broking itself is commoditised and earnings hinge on F&O volumes that SEBI can curb.

Bull: Q2 FY27 revenue rose 47% YoY to Rs 1,502 crore and net profit rose 54% to Rs 725 crore with a 48% net margin, as total transacting users grew 27% and customer assets 46%.

Bear: Equity derivatives still supplied 44.8% of total income in Q2 FY27, so any further SEBI tightening on F&O or a market downturn hits the core profit engine directly at a ~39x forward P/E.

Verdict: Great business, wrong price — at ~77x forward earnings the risk-reward is poor, so avoid chasing it here.

Moat: Leading domestic transformer and industrial-systems franchise with scale and a record order book, but it operates in a cyclical, competitive capital-goods market with no pricing monopoly.

Bull: Q2 FY27 was its best quarter — sales up 30% YoY to Rs 3,802 crore, net profit up 44% to Rs 409 crore, and a record order book of Rs 23,646 crore (+58% YoY) — and Motilal Oswal raised its target to Rs 1,140.

Bear: Despite the record quarter the stock fell 4.4% on 6 Nov to Rs 773, and at ~77x FY27E earnings the valuation leaves no room for the midcap sell-off or any order-execution slip.

Verdict: A wide-moat healthcare leader growing ~20%+, but fairly valued at ~48x forward earnings — hold.

Moat: Asia's foremost integrated healthcare provider — India's largest hospital chain plus Apollo Pharmacy, diagnostics and Apollo 24/7 — with a brand and scale rivals cannot quickly replicate.

Bull: Q2 FY27 (reported 4 Nov) delivered revenue of Rs 7,615 crore (+23% YoY) and PAT of Rs 630 crore (+32% YoY), with SMIFS projecting 17% revenue CAGR over FY26-28E and a Rs 10,230 target.

Bear: At ~48x FY27E earnings and 11.4x book, the market already pays up for the growth, and new-hospital gestation plus the CEO exit on 14 Nov add near-term drag.

Verdict: A wide-moat compounder, but at 35x forward earnings with PAT growth in single digits this quarter, it is fairly priced — hold.

Moat: India's largest mutual fund manager by AUM with a trusted HDFC brand, HDFC Bank distribution, 11.1% market share and a 67.1% equity-oriented AUM mix that earns the highest yields.

Bull: Q2 FY27 quarterly average AUM hit Rs 9.69 lakh crore (+10% YoY), revenue grew 14% to Rs 1,170 crore and operating profit 16%, with Motilal Oswal retaining BUY at a Rs 2,900 target.

Bear: Reported PAT grew only 4% YoY as a 45% jump in tax expense swallowed operating gains, closing AUM was flat sequentially, and market share eased to 11.1% while the industry grew faster.

Verdict: The market leader at a discount to its IPO price and broker targets, with a 50%+ ROE — a buy at this price for a long-term holder.

Moat: India's largest AMC with a 15.3% mutual-fund market share, Rs 12.5 lakh crore MF AUM and the SBI distribution machine behind it, at an industry-leading ~8bp opex ratio.

Bull: The stock trades at Rs 499.55, 13% below its Rs 574 IPO price (listed 21 Jul 2026) and below broker targets of Rs 590-720, while MF QAAUM grew 9% YoY to Rs 13.1 lakh crore in Q2 FY27 with a 15% market share.

Bear: Q2 FY27 opex jumped 22% YoY and PAT fell 20% QoQ to Rs 701 crore, PMS/advisory AUM fell 17% YoY on a large mandate reallocation, and promoters hold 88.19% so free float is tiny.

Verdict: Quality hospitals at a cooling price — hold and accumulate on dips rather than chase, with valuation still demanding.

Moat: Premium hospital brand concentrated in NCR/North India with high ARPOB and 77% occupancy, but regional concentration and dependence on a few flagship hospitals limit the moat versus Apollo's national scale.

Bull: Q2 FY27 gross revenue grew 20% YoY to Rs 3,219 crore with operating EBITDA up 18% and international revenue up 33%, and the stock is ~21% below its 52-week high after a year of derating.

Bear: Q2 PAT growth slowed to ~10% YoY as depreciation and interest from new beds bit, and at ~49x FY27E earnings the stock still needs flawless ramp-up of its 3,000+ bed expansion pipeline.

Verdict: At 4.3x forward earnings, 0.56x book and a 5.6% yield, the market is pricing in the REC drag — a buy for income-plus-value at Rs 329.

Moat: Maharatna PSU lender dominating power-sector finance with sovereign backing, a Rs 11.89 lakh crore group loan book and 20%+ ROE, but lending is concentrated in one sector.

Bull: Standalone Q2 FY27 PAT rose 11.8% YoY to Rs 4,987 crore, the board declared a Rs 4.10 interim dividend (5.6% yield), and gross Stage-III assets improved to 0.91%.

Bear: Consolidated Q2 PAT fell 2% YoY to Rs 7,682 crore because subsidiary REC's profit dropped 21.2%, and the pending PFC-REC merger (88 PFC shares per 100 REC, effective Apr 2027) hangs over the stock, which is 32% below its 52-week high.

Verdict: A solid ports growth story at 36.9x forward earnings with a 10% analyst upside to Rs 372 — fairly priced, hold.

Moat: Long-dated port concessions and a 186 MTPA network with captive JSW cargo give scale, but ports are capital-heavy and face Adani-led competition on tariffs.

Bull: H1 FY27 consolidated operating revenue grew 18% YoY to Rs 2,926 crore with India cargo up 10%, and capacity is targeted to rise from 186 to 300 MTPA by FY28.

Bear: Fujairah contributed no volume and a Rs 16 crore H1 loss versus Rs 134 crore EBITDA a year ago, Q2 PAT fell, and free cash flow is negative on heavy capex.

Verdict: At 31.5x forward earnings while earnings are falling and the order book is thin, the submarine hope is already more than priced in — avoid until P75(I) is actually signed.

Moat: India's only yard to have built and delivered Scorpene-class submarines, giving it a strategic edge in naval programmes, but it depends on a single government customer and lumpy awards.

Bull: The Project 75(I) programme for six next-generation submarines (~Rs 70,000-90,000 crore) is in its final approval stage and underpins management's Rs 1 lakh crore FY27 order-booking target, and the company holds Rs 10,832 crore net cash.

Bear: Q2 FY27 revenue fell 16.5% and PAT fell 53.8% to Rs 346 crore on ~Rs 413 crore of provisions, EPS missed consensus by 40%, and the order book shrank 40% YoY to Rs 16,443 crore.

Verdict: A high-quality AMC compounding AUM at ~20%, but 36.2x forward earnings already reflects it — hold at Rs 1,065.

Moat: Rs 8.68 lakh crore AUM with 9.02% MF market share, 35% ROE and a 94% payout give scale and distribution strength, but fees are market-linked and compressible.

Bull: Q2 FY27 delivered a record quarterly operating profit of Rs 523 crore (+25% YoY) as MF QAAUM grew 20% YoY to Rs 7.87 lakh crore with market-share gains.

Bear: Reported Q2 PAT fell 5.9% YoY to Rs 324 crore after a Rs 96.76 crore one-time SEBI settlement charge on the Yes Bank AT-1 case, and the stock sits 16% below its 52-week high.

Verdict: Momentum and deal wins are real, but at ~30x forward earnings and above street targets after a 30% one-month run, risk-reward at this price is poor — avoid chasing it here.

Moat: A focused ER&D pure-play with deep L&T parentage and sticky engineering relationships in sustainability and mobility, but it competes in a crowded IT-services market with limited pricing power.

Bull: Q2 FY27 revenue grew 12.1% YoY to Rs 3,040 crore with EBIT margin up 220 bps to 16.3%, large-deal TCV exceeded $200 million (over half AI-led), and management reiterated a 13-15% revenue CAGR aspiration.

Bear: The stock is up ~30% in a month and trades above the analyst consensus target (~Rs 3,764-3,850), Q2 profit was flattered by a Rs 165 crore one-time gain from the SWC divestment, and Tech segment growth is guided muted for Q3.

Verdict: Revenue is compounding fast but profits are not, and 59.9x forward earnings leaves no margin for error — avoid at Rs 723.

Moat: A leading hospital network in Andhra Pradesh and Telangana with rising ARPOB (Rs 48,277, +14.9% YoY) and scale across tier-2/3 cities, but new hospitals dilute returns.

Bull: Q2 FY27 consolidated revenue jumped 39.9% YoY to Rs 1,344 crore, the new Kondapur hospital reached 70% occupancy, and IP volumes rose 27%.

Bear: Q2 PAT grew only 3.6% YoY to Rs 74.6 crore and H1 PAT fell 29% YoY, as oncology launches and new hospitals raised fixed costs and interest/depreciation.

Verdict: A superb wide-moat franchise at a fair-to-rich price, so hold rather than chase at Rs 1,331.

Moat: One of only two depositories in India, with entrenched network effects across DPs, issuers and investors and ROE above 30%.

Bull: Q2 FY27 was seasonally strong with H1 income of Rs 685.2 crore and profit of Rs 307.8 crore, as IPO activity and demat additions stayed strong.

Bear: At 47.6x forward earnings and a consensus target of Rs 1,362 (just 2% above the price), the market-linked revenue leaves little room for a weak equity-issuance quarter.

Verdict: The corvette win transforms the order book, but at 27x forward earnings with a visible post-FY27 cliff, the price already reflects the good news — hold.

Moat: One of only a handful of Indian yards that can build frontline naval warships, with a captive Ministry of Defence customer, but orders are lumpy and pricing is set by a single buyer.

Bull: GRSE signed a Rs 32,000 crore Indian Navy contract on 2 November 2026 for five Next Generation Corvettes — ~4.6x FY26 revenue — after Q1 FY27 revenue rose 38.5% and PAT 44%.

Bear: Goldman Sachs initiated with a Sell (TP Rs 1,515), forecasting revenue falling to Rs 5,060 crore by FY29 and EBITDA CAGR of -19.3% FY26-29 once current programmes end, and the stock is ~36% below its Rs 3,339 52-week high.

Verdict: Extraordinary AI-driven growth at a forward P/E of ~48x after a 35% correction from the highs makes it a buy on risk-reward, but only for investors comfortable with lumpy orders and weak cash conversion.

Moat: India's leading indigenous high-end computing OEM with integrated design and manufacturing and marquee AI/HPC wins, but it assembles third-party chips (NVIDIA etc.) with no proprietary silicon and lumpy, concentrated orders.

Bull: Q2 FY27 was a record quarter with revenue up 335.7% YoY to ₹1,323 crore and PAT up 334.8% to ₹137 crore, backed by a ₹2,629 crore order book plus ₹653 crore of L1 positions.

Bear: The stock fell 6.3% on Nov 6 and is ~35% below its August 52-week high of ₹5,813, while TTM operating cash flow was negative (₹-5.69 billion) despite the profit surge, showing lumpy, working-capital-heavy execution.

Verdict: Great defence niche at 55.6x forward earnings after a very weak quarter — avoid at this price until H2 execution proves the guidance.

Moat: Vertically integrated defence-electronics supplier with 35+ years of DRDO/BrahMos/HAL qualifications that are slow to replicate, but revenue is lumpy and customer-concentrated.

Bull: Management kept FY27 guidance unchanged at 20-25% revenue growth with 35-40% EBITDA margin, backed by a Rs 2,698 crore order book including negotiated orders and Rs 929 crore of Q2 inflows.

Bear: Q2 FY27 revenue fell 56.7% and PAT 55.3% YoY to Rs 22 crore, and the stock dropped 4.85% on 6 Nov 2026, so the promised H2 recovery still has to be delivered.

Verdict: The order book is real but margins are not, and ~100x trailing earnings prices in a flawless rebound — avoid at Rs 1,953.

Moat: A PSU equipment maker with a huge order book but 5% ROE, 3.3% net margins and 191 debtor days — scale without pricing power or consistent profitability.

Bull: Management raised FY27 revenue growth guidance to over 35% after Q2 revenue rose 42% YoY to Rs 1,192 crore, with the order book at Rs 21,388 crore including a Rs 5,400+ crore high-speed rail order.

Bear: Q2 FY27 PAT still fell 30.6% YoY to Rs 33 crore as material costs rose 51.6% and operating margin compressed to 6.7%, so the order book is not yet converting into profit.

Verdict: A wide-moat duopoly at ~37x forward earnings with profit growing far slower than revenue — avoid until margins prove they can recover.

Moat: India's first and largest depository in a two-player duopoly with CDSL, holding the demat infrastructure for the whole market with very high switching costs.

Bull: Q2 FY27 (Sep 2026) sales rose 36% YoY to Rs 546 crore and net profit rose 11% to Rs 122 crore, with banking-services revenue more than doubling and custody/e-voting share intact.

Bear: The stock is down about 31% year-to-date and 37% over one year, hit a fresh all-time low of Rs 717.50 on Oct 22, 2026, and trades below its Rs 800 IPO price as front-loaded tech and cyber-security spending squeezes core margins.

Verdict: A monopoly order book at about 58x FY27E earnings whose FY27 rebound depends entirely on fixing the supply chain — hold at this price.

Moat: Sole domestic manufacturer of guided missiles, torpedoes and allied systems for the Indian armed forces, 74.9% owned by the Government of India, with a Rs 26,176 crore order book.

Bull: The order book of Rs 26,176 crore is 10.7x FY26 sales, Q1 FY27 revenue jumped 131% YoY to Rs 572 crore, and Motilal Oswal expects FY27 revenue of about Rs 42.3 billion with a Rs 1,307 crore Navy heavyweight-torpedo contract signed 15 Oct 2026.

Bear: FY26 revenue fell 27% YoY to Rs 24.4 billion after Akash and Astra Mk1 deliveries slipped on delayed radars and seekers, Q1 gross margin was 51.5% versus a 60% estimate, and the stock is 35% below its 52-week high in a Stage 4 downtrend.

Verdict: Explosive, guidance-backed growth at a still-demanding price after a 37% drawdown from the high — hold, with the risk-reward only turning attractive on further weakness.

Moat: 15+ year sole-supplier relationship with Bloom Energy for solid-oxide fuel-cell hot boxes plus nuclear and aerospace precision work creates high switching costs, but Bloom dominates the order book.

Bull: Q2 FY27 revenue jumped 200% YoY to Rs 406.8 crore with EBITDA margin 24.4% and PAT of Rs 59.8 crore, and management reaffirmed 80% FY27 revenue growth with record H1 order inflows of Rs 4,102 crore.

Bear: The stock fell 5% on 6 Nov (its lower circuit that day), is 37% below its Jun 2026 high of Rs 8,714, and the Bloom fuel-cell order book of Rs 5,977 crore is 67% of the total, so one customer drives the story.

Verdict: Strong quarter, but the valuation already assumes the MIGM and Pinaka orders land on schedule — avoid at about 109x trailing earnings.

Moat: DRDO production agency for naval mines (MIGM) and defence-electronics supplier with proprietary sensor/fuze IP, but still small-scale with lumpy, development-heavy revenue.

Bull: Q2 FY27 consolidated revenue rose 72% YoY to Rs 388 crore with PAT up 54% to Rs 46 crore, an all-time-high order book of Rs 1,765 crore, and management guiding 35-45% revenue growth with the book above Rs 2,000 crore by Mar 2027.

Bear: The stock trades at about 109x trailing earnings with 35.6% of the promoter holding pledged, 194 debtor days and negative operating cash flow, while the big MIGM order is still not placed and the Rs 1,550 crore Premier Explosives buy plus Rs 986 crore open offer add integration and dilution risk.

Verdict: A genuine defence order-book story that is already priced at about 60x FY27E earnings, so hold at this price and buy only on execution or a pullback.

Moat: Long-standing RF/microwave subsystem supplier to DRDO, HAL and the armed forces with programme-specific IP, but a small, lumpy, customer-concentrated order flow.

Bull: The Rs 2,205 crore HAL order for 122 Uttam AESA radar antenna units in Q2 FY27 lifts the group order book to about Rs 4,341 crore, roughly 3.8x FY26 sales, with management guiding FY27 revenue of Rs 1,300-1,400 crore.

Bear: Q1 FY27 revenue fell 11.5% YoY to Rs 177 crore and PAT fell 24% YoY, while debtor days of 216 and a 537-day cash conversion cycle show execution and collections remain slow.

Verdict: The fastest revenue ramp in this set, but at about 60x FY27E earnings on a thin, capex-heavy earnings base — hold, not chase, at this price.

Moat: India's only listed pure-play GPU cloud with NVIDIA Blackwell capacity, a Rs 1,000 crore sovereign AI contract and L&T data-centre access, but GPUs obsolesce fast and hyperscalers can undercut it.

Bull: Q2 FY27 revenue surged 411% YoY to Rs 223.8 crore with a 76.6% operating margin and PAT of Rs 72.7 crore, plus a multi-year Rs 1,000 crore sovereign AI contract through Jun 2029 and a 5.4 MW Blackwell expansion lifting capacity 59% to 14.6 MW.

Bear: FY26 closed with a net loss of Rs 16 crore because GPU depreciation outran utilisation, free cash flow was negative Rs 1,140 crore in FY26, and the stock is down 31% in a month and 36% off its 52-week high.

Verdict: Fast-growing but expensive, cash-hungry and priced on a data-centre pivot that has not yet sold anything — avoid at this price.

Moat: Glass-lined reactors and turnkey pharma/chemical equipment is a competitive, capital-intensive fabrication business with no proprietary IP, and the new GScale data-centre venture is unproven.

Bull: Q2 FY27 revenue jumped 62.3% YoY to Rs 296.6 crore with PAT up 37.9% to Rs 28.2 crore, H1 revenue up 53% to Rs 544.3 crore, an order book of about Rs 1,000 crore, and management targets over Rs 1,450 crore FY27 revenue with GScale contributing over Rs 250 crore in Q4.

Bear: The stock trades at about 79-88x trailing earnings with ROE of only 10.7% and negative free cash flow in every year FY22-FY26, and the GScale data-centre revenue (from 15 Dec 2026) is a management target, not yet a rupee of sales.

Verdict: Fast-growing micro-cap defence name, but at ~50x trailing earnings with a tiny order book and lumpy execution it is fairly priced at best — hold, do not chase.

Moat: Small project-based defence test-equipment supplier with no scale, IP or switching-cost advantage versus larger defence primes and lumpy government/DRDO tender revenue.

Bull: H1 FY27 revenue jumped 91% YoY to Rs 34.96 crore and PAT rose 151% to Rs 4.76 crore, and management guides 25-30% FY27 revenue growth with a Rs 189 crore identified opportunity pipeline.

Bear: The stock trades at roughly 38-52x trailing earnings on a thin Rs 20 crore order book, revenue is heavily H2-weighted and tender-dependent, and the company secretary/compliance officer resigned effective November 25, 2026.

Verdict: Real AI-infrastructure growth at a pre-IPO mark of ~41x sales with a 1% net margin and $1.1bn of net debt — avoid at the reported valuation.

Moat: Hiranandani-backed sovereign AI cloud with an estimated 60-70% of India's installed GPU capacity and an Nvidia AI Compute Partnership, but the edge is bought with debt-funded GPUs, not proprietary technology.

Bull: Standalone revenue nearly doubled in FY25 to Rs 900.84 crore (+94% YoY) and the company is targeting an India IPO in Jan-Mar 2027 to fund GPU and data-centre expansion as AI demand surges.

Bear: FY25 PAT was only Rs 11.05 crore (1.2% margin, down 24% YoY) while carrying about $1.1 billion of net debt and a $12 billion Nvidia GPU order book, at a July 2026 pre-IPO valuation of ~$3.9 billion — roughly 41x FY25 sales.